Goldman Sachs
TVRD

Goldman Sachs’s Tvardi Therapeutics TVRD Stock Holding History

Goldman Sachs’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$76K Sell
23,898
-9,233
-28% -$36.2K ﹤0.01% 6244
2025
Q4 		$142K Buy
33,131
+9,102
+38% +$81.6K ﹤0.01% 6126
2025
Q3 		$936K Buy
+24,029
New +$684K ﹤0.01% 5072
2024
Q3 		– Sell
-10,824
Closed -$101K – 6132
2024
Q2 		$101K Buy
10,824
+9,389
+654% +$224K ﹤0.01% 5403
2024
Q1 		$47K Sell
1,435
-4,395
-75% -$114K ﹤0.01% 5330
2023
Q4 		$156K Buy
5,830
+2,084
+56% +$86.3K ﹤0.01% 5217
2023
Q3 		$227K Sell
3,746
-4,194
-53% -$393K ﹤0.01% 4996
2023
Q2 		$809K Sell
7,940
-494
-6% -$68K ﹤0.01% 4481
2023
Q1 		$1.49M Buy
8,434
+225
+3% +$75.3K ﹤0.01% 4084
2022
Q4 		$3.17M Buy
8,209
+827
+11% +$314K ﹤0.01% 3565
2022
Q3 		$2.49M Buy
7,382
+3,345
+83% +$1.21M ﹤0.01% 3787
2022
Q2 		$1.33M Buy
4,037
+483
+14% +$169K ﹤0.01% 4399
2022
Q1 		$1.55M Buy
3,554
+53
+2% +$21.8K ﹤0.01% 4448
2021
Q4 		$1.53M Sell
3,501
-5,027
-59% -$2.53M ﹤0.01% 4474
2021
Q3 		$4.74M Sell
8,528
-2,009
-19% -$1.01M ﹤0.01% 3414
2021
Q2 		$5.41M Sell
10,537
-1,768
-14% -$1.12M ﹤0.01% 3273
2021
Q1 		$9.62M Sell
12,305
-4,388
-26% -$3M ﹤0.01% 2600
2020
Q4 		$9.09M Sell
16,693
-406
-2% -$213K ﹤0.01% 2547
2020
Q3 		$7.83M Buy
17,099
+8,122
+90% +$4.72M ﹤0.01% 2529
2020
Q2 		$5.53M Buy
8,977
+3,082
+52% +$1.7M ﹤0.01% 2730
2020
Q1 		$2.8M Sell
5,895
-1,118
-16% -$608K ﹤0.01% 3075
2019
Q4 		$4.07M Sell
7,013
-1,338
-16% -$939K ﹤0.01% 3127
2019
Q3 		$5.5M Buy
8,351
+5,864
+236% +$4.87M ﹤0.01% 2792
2019
Q2 		$1.93M Buy
2,487
+897
+56% +$630K ﹤0.01% 3587
2019
Q1 		$1.12M Sell
1,590
-1,045
-40% -$626K ﹤0.01% 3992
2018
Q4 		$1.23M Sell
2,635
-1,797
-41% -$1.16M ﹤0.01% 3852
2018
Q3 		$3.82M Sell
4,432
-1,454
-25% -$1.05M ﹤0.01% 3178
2018
Q2 		$4.06M Buy
5,886
+5,050
+604% +$2.57M ﹤0.01% 3103
2018
Q1 		$372K Sell
836
-1,353
-62% -$656K ﹤0.01% 4670
2017
Q4 		$964K Buy
2,189
+1,285
+142% +$586K ﹤0.01% 4356
2017
Q3 		$446K Sell
904
-1,449
-62% -$726K ﹤0.01% 5179
2017
Q2 		$1.3M Buy
2,353
+2,026
+620% +$1.29M ﹤0.01% 4217
2017
Q1 		$216K Sell
327
-516
-61% -$276K ﹤0.01% 5684
2016
Q4 		$282K Buy
843
+74
+10% +$23.7K ﹤0.01% 5532
2016
Q3 		$231K Sell
769
-13
-2% -$2.82K ﹤0.01% 5704
2016
Q2 		$135K Buy
782
+430
+122% +$93.6K ﹤0.01% 5973
2016
Q1 		$79K Buy
+352
New +$105K ﹤0.01% 6198

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Goldman Sachs's TVRD Position: Q1 2026 in Review

Goldman Sachs reduced its Tvardi Therapeutics (TVRD) stake by 28% in Q1 2026, selling an estimated $36.2K and leaving 23,898 shares worth $76K. The position accounts for ﹤0.01% of the portfolio, ranked #6244.

Goldman Sachs first reported a position in TVRD in Q1 2016 and has held it in 37 quarters since. The position peaked at $9.62M in Q1 2021. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Goldman Sachs held 23,898 shares of Tvardi Therapeutics worth $76K as of Q1 2026.
  • Goldman Sachs sold 9,233 Tvardi Therapeutics shares in Q1 2026, an estimated $36.2K.
  • Tvardi Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6244 holding.
  • Goldman Sachs first reported a position in Tvardi Therapeutics in Q1 2016 and has held it in 37 quarters since.
  • Goldman Sachs's Tvardi Therapeutics position peaked at $9.62M in Q1 2021.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.